Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral naltrexone + bupropion for methamphetamine use disorder
ACTRN12623000866606Phase 4Completed
- Sponsor
- St Vincent's Hospital Sydney
- Start
- Mar 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of naltrexone + bupropion, naltrexone and bupropion in methamphetamine use disorder (MUD) and stimulant use disorder (SUD), sponsored by St Vincent's Hospital Sydney. Primary endpoints: Safety and Feasibility. Started Mar 2024; status: completed.
02
Drugs
naltrexone + bupropionnaltrexonebupropion
03
Conditions
methamphetamine use disorder (MUD)stimulant use disorder (SUD)
Beyond the preview
Go deeper on ACTRN12623000866606.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12623000866606.